Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial

Repurposed drugs may reduce morbidity and mortality in patients with hematological disorders who develop COVID-19 illness. 112 patients with predominantly hematological illnesses were randomized to receive standard of care, ivermectin 12 mg [Iv 12] or 24 mg [Iv24] for asymptomatic, mild, or moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Biju, Moorthy, Mahesh, Kulkarni, Uday, Selvarajan, Sushil, Rupali, Priscilla, Christopher, D. J., Balamugesh, T., Rose, Winsley, Lakshmi, Kavitha M., Devasia, Anup J., Fouzia, N. A., Korula, Anu, Lionel, Sharon, Abraham, Aby, Mathews, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135993/
https://www.ncbi.nlm.nih.gov/pubmed/35669353
http://dx.doi.org/10.1007/s12288-022-01546-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135993/
https://www.ncbi.nlm.nih.gov/pubmed/35669353
http://dx.doi.org/10.1007/s12288-022-01546-w

Ejemplares similares